Roche, Trimeris withdraw application for Fuzeon injection device

10/3/2007 | News & Observer (Raleigh, N.C.), The · Forbes

Roche Holding subsidiary Hoffmann-La Roche and Trimeris said they are withdrawing their FDA application to market the Biojector 2000 needle-free injection device in combination with HIV drug Fuzeon, following a comprehensive evaluation of a clinical trial and a delay in getting regulatory approval. The companies believe the device isn't an ideal substitute for the delivery of the drug among "all treatment-experienced patients" despite its potential benefits, a Roche official said.

View Full Article in:

News & Observer (Raleigh, N.C.), The · Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Director of Product Planning Development; Market Planning, Innovation
Blue Cross Blue Shield of Massachusetts
Quincy , MA
Director, Payer Marketing
Avalere Health
Washington, DC
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX